Alterity Therapeutics Reports Cessation of Securities (ATH)

Alterity Therapeutics Limited filed a Form 6-K with the SEC on June 15, 2026, reporting a notification of cessation of securities. The filing includes Exhibit 99.1, which details the cessation of specific securities (ATH). The document was signed by Julian Babarczy, the Chairman of the Board. This report is incorporated by reference into several of the company’s existing Registration Statements on Form S-8 and Form F-3. As a development-stage enterprise, Alterity Therapeutics continues to provide routine regulatory updates regarding its capital structure and outstanding securities. No clinical trial data, financial results, or strategic partnerships were disclosed in this specific filing. The primary focus of the report is the administrative update concerning the expiration or cancellation of previously issued securities, a common occurrence in the management of equity incentive plans or lapsed options.